Fortrea Holdings Inc.

NASDAQ:FTRE

Biotechnology

Healthcare
$20.50 -0.46%

-$0.07 today

Market cap
$1.94B
Beta
2.11
P/E (TTM)
-3.1
EPS (TTM)
-$4.90
52W Low $4.36High $18.67

Volume 1.59M

Average 1.31M

FTRE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Fortrea Holdings Inc.NASDAQ: FTRE

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation dips below year-ago levels

Q2 FY2026 stock-based compensation of $12.6M fell 44.5% year over year, behind the +21.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 10.5% from the prior quarter. Over 3 fiscal years it compounded at +43.1% a year.

Context

  • Stock-based compensation amounted to 2.7% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -44.5% toward the trailing-twelve-month pace of +21.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$12.6M+10.5% QoQ
Last fiscal yearDec 2025
$74.4M+27.4% YoY
LTMJun 2026
$61.1M+21.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.5%——
1 year+27.4%——
3-year CAGR+43.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
74.4M USD
Year-over-year change
+27.4%
4-year CAGR
+28.3%

Stock-Based Compensation vs competitors

How FTRE compares with its peers on the latest reported figures

  • FTRE's LTM Jun 2026 stock-based compensation of $61.1M is the largest of the 3 companies compared; the peer median is $27.91M.
  • Its year-over-year change of +21.5% is the highest of 3, against a peer median of -17.1%.
  • Stock-based compensation amounts to 2.3% of revenue for FTRE, versus a peer median of 4.4%.
FTRE Competitors Peer median
Stock-Based Compensation for FTRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FTREFortrea Holdings Inc.LTM Jun 2026$61.1M +21.5%+43.1%2.3%
CERTCertara, Inc.LTM Mar 2026$33.33M +1.7%+2.9%7.9%
MEDPMedpace Holdings, Inc.LTM Sep 2026$22.49M -35.8%+17.6%0.8%
Peer median (excluding FTRE) $27.91M-17.1%+10.2%4.4%

Competitors are the stored peer set for FTRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income98M186.2M(25.2M)(271.5M)(986.2M)
Depreciation & Amortization166.3M93.6M98M86.9M78M
Deferred Income Tax(30.2M)(16.5M)(41.6M)(24.6M)(32M)
Stock-Based Compensation27.5M25.4M42.7M58.4M74.4M
Change in Working Capital(127.2M)(248.2M)26.9M364.5M114.7M
Accounts Receivables(187.6M)(108.4M)(53.4M)309.9M70.9M
Inventory00000
Accounts Payables(6.2M)24.8M55.3M7.2M(109.9M)
Other Working Capital66.6M(164.6M)25M47.4M153.7M
Other Non-Cash Items35.4M42.2M67.6M49.1M864.6M
Operating Cash Flow169.8M82.7M168.4M262.8M113.5M
Capital Expenditures(26.5M)(54.4M)(40.3M)(25.5M)(25.2M)
Acquisitions (Net)000276.6M0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities300K400K8.5M500K39.6M
Investing Cash Flow(26.2M)(54M)(31.8M)251.6M14.4M
Debt Repayment001.62B(482.7M)(76.3M)
Common Stock Issued00000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(128.5M)(6.3M)(1.76B)(15.1M)0
Financing Cash Flow(128.5M)(6.3M)(140.8M)(497.8M)(76.3M)
Effect of Forex Changes(800K)(6.6M)2.4M(6.7M)4.5M
Net Change in Cash14.3M15.8M(1.8M)9.9M56.1M
Free Cash Flow143.3M28.3M128.1M237.3M88.3M

Fortrea Holdings Inc.

NASDAQ:FTRE

Intrinsic Alpha fair value

Locked

Current Price

$20.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.